Considering the fact that both CLL cells and T cells, including the Treg microenvironment, can be targeted by CTLA-4 blocking antibody in a possible immunotherapy approach, our current findings may be of potential clinical relevance. This evidence concerns the gene CTLA4 and B-cell chronic lymphocytic leukemia.